StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Total operating and finance lease liabilities by Year

Total operating and finance lease liabilities ($M) ($M)

QuarterlyAnnual

Moderna Total operating and finance lease liabilities: $715M in FY2025, down 4.3% from a year earlier.

Latest, FY2025
715
Period ended Dec 31, 2025
Change on a year earlier
-4.3%
747 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-Q (filed 2026-07-31) ↗

Reported in Form 10-Q / 10-K Note 10 (Leases).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal operating and finance lease liabilities ($M) ($M)Year on yearSource
FY2025Dec 31, 2025715-4.3%Form 10-Q (filed 2026-07-31) ↗
FY2024Dec 31, 2024747-39.9%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 20231,243+3.6%Form 10-K (filed 2025-02-21) ↗
FY2022Dec 31, 20221,200+31.0%Form 10-K (filed 2024-02-23) ↗
FY2021Dec 31, 2021916+286.5%Form 10-K (filed 2023-02-24) ↗
FY2020Dec 31, 2020237+74.4%Form 10-K (filed 2022-02-25) ↗
FY2019Dec 31, 2019136+25.4%Form 10-K (filed 2021-02-26) ↗
FY2018Dec 31, 2018108–Form 10-K (filed 2020-02-27) ↗

Breakdown

What makes up total operating and finance lease liabilities

Cite this data

StockData. (2026). Moderna Total operating and finance lease liabilities ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/tot-lease-liab

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.